• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 263/34

Total number of patents in this class: 248

10-year publication summary

15
21
16
18
15
17
20
13
10
3
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Theravance Biopharma R&D IP, LLC
425
25
Pro Farm Group, Inc.
124
10
DSM IP Assets B.V.
5432
8
Siemens Medical Solutions USA, Inc.
1470
7
Boehringer Ingelheim International GmbH
4496
6
Astellas Pharma Inc.
1036
5
Nippon Shinyaku Co., Ltd.
322
5
Takeda Pharmaceutical Company Limited
2716
4
Arizona Board of Regents on behalf of Arizona State University
2864
4
Otsuka Pharmaceutical Co., Ltd.
1502
4
Janssen Pharmaceutica N.V.
3226
3
Syngenta Crop Protection AG
6537
3
Allergan, Inc.
2204
3
Bayer Pharma AG
1025
3
Amgen Inc.
4362
3
Beiersdorf AG
3083
3
Blade Therapeutics, Inc.
15
3
Incyte Corporation
1063
3
Northeastern University
1276
3
Rutgers, The State University of New Jersey
1956
3
Other owners 140